{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:06:41Z","timestamp":1790806001918,"version":"4.1.0"},"reference-count":39,"publisher":"Journal of Biological Methods","issue":"5","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HPR"],"abstract":"<jats:p>This is a comprehensive review of the literature regarding the use of Deutetrabenazine in treating chorea associated with Huntington&amp;rsquo;s disease. Unfortunately, treatment has been limited for many aspects of this neurodegenerative disease. The present investigation presents the background, evidence, and indications for the use Deutetrabenazine in the setting of Huntington&amp;rsquo;s disease. Huntington&amp;rsquo;s disease is characterized by a variety of motor, psychiatric, and cognitive symptoms with chorea being one of the more notable ones. Chorea is a movement disorder present in multiple neurologic diseases that causes involuntary and irregular muscle movements theorized to be stemming from high dopamine levels. Deutetrabenazine is thought to function as an inhibitor of the VMAT2 vesicular monoamine transporter resulting in decreased monoamine release, including dopamine, in the synaptic cleft which has a therapeutic effect in management of chorea. This drug was approved by the FDA in 2017 with a specific indication for tardive dyskinesia and choreiform movement in Huntington&amp;rsquo;s disease. Currently, there is no definitive treatment for Huntington&amp;rsquo;s disease. Thus, management is primarily focused on symptom management with the use of a variety of pharmaceutical agents. Chorea is one of the many manifestations that significantly alter the quality of life of many patients. Deutetrabenazine is a promising new option for the treatment of chorea in the setting of Huntington&amp;rsquo;s disease. Although studies so far have displayed mixed results, further research, including head-to-head studies, is necessary to elucidate the true potential of this drug.<\/jats:p>","DOI":"10.52965\/001c.36040","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T04:08:56Z","timestamp":1656389336000},"page":"1","source":"Crossref","is-referenced-by-count":17,"title":["deutetrabenazine for the treatment of chorea associated with \u00a0 Huntington\u2019s disease"],"prefix":"10.14440","volume":"10","author":[{"given":"Harshit","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wil","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cain","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathya","family":"Kikkeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juyeon","family":"Kakazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"D. Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"D. Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5574","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1002\/mds.25996","article-title":"Chorea associated with Huntington's disease: to treat or not to treat?","volume":"29","author":"Joseph Jankovic","year":"2014","journal-title":"Movement Disorders","ISSN":"https:\/\/id.crossref.org\/issn\/0885-3185","issn-type":"print"},{"issue":"1","key":"ref2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","article-title":"Current Pharmacological Approaches to Reduce Chorea in Huntington\u2019s Disease","volume":"77","author":"Emma M. Coppen","year":"2017","journal-title":"Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/0012-6667","issn-type":"print"},{"issue":"10","key":"ref3","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1212\/wnl.0b013e3182885eb3","article-title":"Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"80","author":"O. Suchowersky","year":"2013","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"issue":"4","key":"ref4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/03007995.2018.1435518","article-title":"Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United States","volume":"34","author":"Victor W. Sung","year":"2018","journal-title":"Current Medical Research and Opinion","ISSN":"https:\/\/id.crossref.org\/issn\/0300-7995","issn-type":"print"},{"issue":"6","key":"ref5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nbt0617-493","article-title":"First deuterated drug approved","volume":"35","author":"Charles Schmidt","year":"2017","journal-title":"Nature biotechnology","ISSN":"https:\/\/id.crossref.org\/issn\/1087-0156","issn-type":"print"},{"issue":"8","key":"ref6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14737175.2018.1500178","article-title":"Deutetrabenazine for the treatment of Huntington\u2019s chorea","volume":"18","author":"Hassaan Bashir","year":"2018","journal-title":"Expert Review of Neurotherapeutics","ISSN":"https:\/\/id.crossref.org\/issn\/1473-7175","issn-type":"print"},{"issue":"4","key":"ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11910-017-0739-9","article-title":"Huntington\u2019s Disease\u2014Update on Treatments","volume":"17","author":"Kara J. Wyant","year":"2017","journal-title":"Current Neurology and Neuroscience Reports","ISSN":"https:\/\/id.crossref.org\/issn\/1528-4042","issn-type":"print"},{"issue":"3","key":"ref8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/mds.23967","article-title":"Deep brain stimulation in the treatment of chorea","volume":"27","author":"Thomas C. Edwards","year":"2012","journal-title":"Movement Disorders","ISSN":"https:\/\/id.crossref.org\/issn\/0885-3185","issn-type":"print"},{"issue":"8","key":"ref9","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/mds.25500","article-title":"Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline","volume":"28","author":"Ralf Reilmann","year":"2013","journal-title":"Movement Disorders","ISSN":"https:\/\/id.crossref.org\/issn\/0885-3185","issn-type":"print"},{"key":"ref10","article-title":"Drugs@FDA: FDA-Approved Drugs"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1212\/01.con.0000436155.46909.c3","article-title":"Chorea","volume":"19","author":"Ruth H. Walker","year":"2013","journal-title":"CONTINUUM: Lifelong Learning in Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/1080-2371","issn-type":"print"},{"issue":"6","key":"ref12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nbt0617-493","article-title":"First deuterated drug approved","volume":"35","author":"Charles Schmidt","year":"2017","journal-title":"Nature biotechnology","ISSN":"https:\/\/id.crossref.org\/issn\/1087-0156","issn-type":"print"},{"key":"ref13","article-title":"Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors","year":"2019","journal-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury"},{"issue":"2","key":"ref14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/wnf.0000000000000326","article-title":"Real-world experience with VMAT2 inhibitors","volume":"42","author":"Nicki Niemann","year":"2019","journal-title":"Clinical Neuropharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/1537-162X","issn-type":"print"},{"issue":"18","key":"ref15","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","article-title":"Dopamine depleters in the treatment of hyperkinetic movement disorders","volume":"17","author":"Joseph Jankovic","year":"2016","journal-title":"Expert Opinion on Pharmacotherapy","ISSN":"https:\/\/id.crossref.org\/issn\/1465-6566","issn-type":"print"},{"key":"ref16","article-title":"Carvedilol Therapy and CYP2D6 Genotype - PubMed"},{"issue":"8","key":"ref17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14737175.2018.1500178","article-title":"Deutetrabenazine for the treatment of Huntington\u2019s chorea","volume":"18","author":"Hassaan Bashir","year":"2018","journal-title":"Expert review of neurotherapeutics","ISSN":"https:\/\/id.crossref.org\/issn\/1473-7175","issn-type":"print"},{"issue":"2","key":"ref18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/1060028018797110","article-title":"Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals","volume":"53","author":"Edward M. Russak","year":"2019","journal-title":"Annals of Pharmacotherapy","ISSN":"https:\/\/id.crossref.org\/issn\/1060-0280","issn-type":"print"},{"issue":"4","key":"ref19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/cts.12754","article-title":"Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV-50717) Compared With Tetrabenazine in Healthy Volunteers","volume":"13","author":"Frank Schneider","year":"2020","journal-title":"Clinical and Translational Science","ISSN":"https:\/\/id.crossref.org\/issn\/1752-8054","issn-type":"print"},{"issue":"5","key":"ref20","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1021\/acs.biochem.7b00765","article-title":"Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine","volume":"57","author":"Sheila H. DeWitt","year":"2018","journal-title":"Biochemistry","ISSN":"https:\/\/id.crossref.org\/issn\/0006-2960","issn-type":"print"},{"issue":"1","key":"ref21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2217\/nmt-2018-0040","article-title":"Deutetrabenazine in the treatment of Huntington's disease","volume":"9","author":"Alby Richard","year":"2019","journal-title":"Neurodegenerative Disease Management","ISSN":"https:\/\/id.crossref.org\/issn\/1758-2024","issn-type":"print"},{"issue":"9557","key":"ref22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/s0140-6736(07)60111-1","article-title":"Huntington's disease","volume":"369","author":"Francis O Walker","year":"2007","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"1","key":"ref23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial","volume":"316","author":"S Frank","year":"2016","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"issue":"8","key":"ref24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamaneurol.2017.1352","article-title":"Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea","volume":"74","author":"Samuel Frank","year":"2017","journal-title":"JAMA neurology","ISSN":"https:\/\/id.crossref.org\/issn\/2168-6149","issn-type":"print"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1212\/01.con.0000436155.46909.c3","article-title":"Chorea","volume":"19","author":"Ruth H. Walker","year":"2013","journal-title":"CONTINUUM: Lifelong Learning in Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/1080-2371","issn-type":"print"},{"issue":"8","key":"ref26","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/s2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Karen E Anderson","year":"2017","journal-title":"The lancet Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/2215-0366","issn-type":"print"},{"issue":"1","key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s40734-017-0051-5","article-title":"Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease","volume":"4","author":"Daniel O. Claassen","year":"2017","journal-title":"Journal of clinical movement disorders","ISSN":"https:\/\/id.crossref.org\/issn\/2054-7072","issn-type":"print"},{"issue":"4","key":"ref28","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/mdc3.12483","article-title":"Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?","volume":"4","author":"Filipe B. Rodrigues","year":"2017","journal-title":"Movement disorders clinical practice","ISSN":"https:\/\/id.crossref.org\/issn\/2330-1619","issn-type":"print"},{"issue":"18","key":"ref29","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1080\/14656566.2019.1674281","article-title":"Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington\u2019s disease: a review of clinical trial data","volume":"20","author":"Daniel O. Claassen","year":"2019","journal-title":"Expert opinion on pharmacotherapy","ISSN":"https:\/\/id.crossref.org\/issn\/1465-6566","issn-type":"print"},{"issue":"1","key":"ref30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40734-017-0067-x","article-title":"Meta-research metrics matter: letter regarding article \u201cindirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease\u201d","volume":"4","author":"Filipe B. Rodrigues","year":"2017","journal-title":"Journal of Clinical Movement Disorders","ISSN":"https:\/\/id.crossref.org\/issn\/2054-7072","issn-type":"print"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/dddt.s138828","article-title":"Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease","volume":"12","author":"Marissa Dean","year":"2018","journal-title":"Drug Design, Development and Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/1177-8881","issn-type":"print"},{"issue":"1","key":"ref32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/jhd-189001","article-title":"Huntington\u2019s Disease Clinical Trials Corner: February 2018","volume":"7","author":"Filipe B. Rodrigues","year":"2018","journal-title":"Journal of Huntington's Disease","ISSN":"https:\/\/id.crossref.org\/issn\/1879-6397","issn-type":"print"},{"issue":"3","key":"ref33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ncl.2009.04.001","article-title":"Huntington Disease and Other Choreas","volume":"27","author":"Francisco Cardoso","year":"2009","journal-title":"Neurologic Clinics","ISSN":"https:\/\/id.crossref.org\/issn\/0733-8619","issn-type":"print"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/dddt.s138828","article-title":"Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease","volume":"12","author":"Marissa Dean","year":"2018","journal-title":"Drug design, development and therapy","ISSN":"https:\/\/id.crossref.org\/issn\/1177-8881","issn-type":"print"},{"issue":"7","key":"ref35","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/arclin\/acx086","article-title":"The Neuropsychology of Huntington's Disease","volume":"32","author":"Julie S Snowden","year":"2017","journal-title":"Archives of Clinical Neuropsychology","ISSN":"https:\/\/id.crossref.org\/issn\/0887-6177","issn-type":"print"},{"issue":"1","key":"ref36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington's disease: a clinical review","volume":"25","author":"P. McColgan","year":"2018","journal-title":"European Journal of Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/1351-5101","issn-type":"print"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.neuroscience.2011.08.052","article-title":"Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function","volume":"198","author":"L.A. Raymond","year":"2011","journal-title":"Neuroscience","ISSN":"https:\/\/id.crossref.org\/issn\/0306-4522","issn-type":"print"},{"issue":"3","key":"ref38","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","article-title":"Identification of Genetic Factors that Modify Clinical Onset of Huntington\u2019s Disease","volume":"162","author":"Jong-Min Lee","year":"2015","journal-title":"Cell","ISSN":"https:\/\/id.crossref.org\/issn\/0092-8674","issn-type":"print"},{"key":"ref39","series-title":"Advances in Experimental Medicine and Biology","isbn-type":"print","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/978-3-319-71779-1_1","article-title":"Clinical features of huntington\u2019s disease","author":"Rhia Ghosh","year":"2018","ISBN":"https:\/\/id.crossref.org\/isbn\/9783319717784"}],"container-title":["Health Psychology Research"],"original-title":[],"link":[{"URL":"https:\/\/api.healthpr.org\/uploads\/file\/asp\/202504071301324b8568038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.healthpr.org\/uploads\/file\/asp\/202504071301324b8568038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T03:36:11Z","timestamp":1760412971000},"score":1,"resource":{"primary":{"URL":"https:\/\/healthpr.org\/journal\/HPR\/10\/5\/10.52965\/001c.36040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,10,11]]}},"URL":"https:\/\/doi.org\/10.52965\/001c.36040","relation":{},"ISSN":["2420-8124"],"issn-type":[{"value":"2420-8124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]}}}